Compugen (NASDAQ:CGEN) Issues Quarterly Earnings Results

Compugen (NASDAQ:CGEN) issued its earnings results on Monday. The biotechnology company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.01, FiscalAI reports. Compugen had a net margin of 47.97% and a return on equity of 47.72%. The company had revenue of $2.60 million for the quarter, compared to analyst estimates of $1.28 million.

Compugen Stock Performance

NASDAQ:CGEN opened at $2.35 on Monday. The company has a market capitalization of $222.20 million, a P/E ratio of 6.35 and a beta of 2.76. The firm has a 50-day moving average price of $2.27 and a two-hundred day moving average price of $2.26. Compugen has a twelve month low of $1.29 and a twelve month high of $3.23.

Institutional Trading of Compugen

Institutional investors and hedge funds have recently modified their holdings of the business. State Street Corp increased its stake in shares of Compugen by 3.9% during the 4th quarter. State Street Corp now owns 393,802 shares of the biotechnology company’s stock worth $603,000 after purchasing an additional 14,701 shares in the last quarter. Two Sigma Investments LP raised its position in shares of Compugen by 10.6% during the 3rd quarter. Two Sigma Investments LP now owns 197,875 shares of the biotechnology company’s stock worth $291,000 after purchasing an additional 18,929 shares during the last quarter. Security National Bank of Sioux City Iowa IA purchased a new stake in Compugen in the 4th quarter valued at approximately $38,000. Franklin Resources Inc. purchased a new stake in Compugen in the 2nd quarter valued at approximately $56,000. Finally, Osaic Holdings Inc. grew its holdings in Compugen by 346.0% during the 2nd quarter. Osaic Holdings Inc. now owns 43,885 shares of the biotechnology company’s stock valued at $78,000 after buying an additional 34,045 shares during the last quarter. Hedge funds and other institutional investors own 12.22% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Leerink Partners decreased their price target on Compugen from $13.00 to $5.00 and set an “outperform” rating on the stock in a research note on Thursday, May 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compugen in a research note on Friday, July 17th. Lake Street Capital started coverage on Compugen in a report on Tuesday, April 7th. They set a “buy” rating and a $6.00 price objective for the company. Finally, Wall Street Zen downgraded Compugen from a “buy” rating to a “hold” rating in a research report on Saturday, May 23rd. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $5.00.

Compugen Company Profile

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.